The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.20
Bid: 19.82
Ask: 20.20
Change: 0.60 (3.09%)
Spread: 0.38 (1.917%)
Open: 19.42
High: 20.50
Low: 19.42
Prev. Close: 19.41
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Update and Outlook

25 Aug 2017 07:00

RNS Number : 9556O
Nanoco Group PLC
25 August 2017
 

 

NANOCO GROUP PLC

("Nanoco" or the "Group" or "Company")

 

Full Year Trading Update and Outlook 

 

Nanoco Group plc (LSE: NANO), the leading developer and manufacturer of cadmium-free quantum dots ("CFQD") and other nanomaterials, provides the following trading update ahead of its preliminary results for the year ended 31 July 2017.

 

It has been a significant year for the Group with solid advances towards the commercialisation of its technology. Unaudited revenues in the year and net cash at the year end were in line with the Board's expectations.

 

Highlights in the year included:

The Group's first commercial orders - to supply CFQD resin to global manufacturer Wah Hong
New routes to market established for CFQDs in Display
TVs using Nanoco CFQD® Fine Color Film™ exhibited at CES in January 2017
Runcorn manufacturing facility became commercially viable
A growing pipeline of potential Display business
Progress in Life Sciences and Lighting markets

 

Display Market

 

The market in Display for CFQDs continues to grow, driven by the increasing appetite for enhanced colour and brightness and the penetration of Ultra High Definition ("UHD") TVs. According to IHS forecasts, 26 million displays will be QD equipped by 2021, with more than 90% of the market cadmium-free. Samsung, with its recently launched QLED brand, is leading the field and sold more than three million QD displays in 2016.

 

While other Display OEMs are embracing CFQD technology, adoption continues to be slow and protracted regulatory change to restrict the use of Cadmium has been unhelpful. However, the recently announced legislation in Europe, banning the use of Cadmium in Displays from October 2019, may be expected to accelerate the move to CFQDs. Several major Taiwanese and Chinese display and TV manufacturers are now actively seeking CFQD solutions, where Nanoco continues to have a competitive lead.

 

Commercialisation

 

Nanoco's Runcorn manufacturing facility has been extensively enhanced - with costs substantially reduced - to enable the Group to supply commercial quantities of its product to fulfil the anticipated volume of future orders. It now has capacity to produce enough CFQDs to supply approximately one million large TVs, operating on a 24/7 shift pattern. Further capacity can be achieved with limited capital expenditure and will be brought online as demand increases.

 

The Group's relationship with Wah Hong Industrial Corporation, its optical film partner, has progressed well. Product from Nanoco / Wah Hong was used by three manufacturers, Hisense, TCL and TPV Philips at CES in January 2017, to demonstrate prototype large screen, UHD, wide colour gamut LCD TVs. Feedback and lead generation from CES was encouraging and further validated the market opportunity. As a result, Wah Hong brought forward its investment in a new coating line which is now commissioned and capable of producing films to fit up to 100 inch TVs. These developments resulted in Wah Hong placing the first commercial order for CFQDs from Nanoco in June 2017.

 

Nanoco's sales pipeline remains full with the same number of OEMs and programmes as stated on 30 June 2017. The Group's key short-term focus is on 10 TV and monitor projects with five companies, however Nanoco will continue to develop further opportunities in the future.

 

Nanoco's other channels to market are via its two licensees, The Dow Chemical Company ("Dow") and Merck KGaA ("Merck"). Dow sells product under the TrevistaTM brand, manufactured in its facility in South Korea. Dow commented that it sees growing interest in cadmium-free quantum dots and has been engaged with several display customers considering adopting quantum dot technology.

 

Nanoco has completed the transfer of our technology to Merck who have successfully produced pilot plant scale quantities of CFQD's at their Darmstadt Germany facility. Merck is carefully watching the development of the cadmium free quantum dot market and will continue to purchase CFQD products from Nanoco until they decide to build their own manufacturing facility. Merck is actively engaged with their potential customers on various CFQD application projects and sells under the LiviluxR brand.

 

In May 2017 Nanoco signed a collaboration and JDA with Kyulux Inc to future proof the Group and ensure it remains at the forefront of next generation products. Under the agreement, Nanoco's CFQDs will be combined with Kyulux's technology to create future generation hybrid OLED / QLED display technology with superior qualities to existing products in the display market.

 

Nanoco has also strengthened its patent portfolio in Electroluminescence with the acquisition of a patent portfolio from Kodak Eastman. Today the Group benefits from c.600 patents and patent applications.

 

Other Markets

 

While Display was the Group's primary focus during the year, Nanoco continued to develop its other target markets of Life Sciences and Lighting. Nanoco's Life Sciences division made further progress in in-vivo optical imaging, diagnosis and targeted therapy of cancer, being awarded an Innovate UK Grant for a VIVODOTS TM programme in conjunction with University College London targeting pancreatic cancer.

 

Lighting continues to make headway, in line with management's expectations, within specialty niche markets including horticulture and photodynamic therapy products.

 

The Board has decided that the Solar business is non-core and has commenced the process to divest that business.

 

People

 

Due to the changes in commercialisation strategy and continued prudent cash management, staff numbers have been reduced to c.80. However, there were also important new hires during the period, including the appointment of David Yao as Senior Vice President of Global Sales, based in Asia.

 

Financial

 

Unaudited revenues and other operating income in the year were in line with the Board's expectations. The balance sheet had unaudited net cash of £5.7 million at 31 July 2017 compared with £8.3 million at 31 January 2017 (31 July 2016: £14.5 million) and was in line with the Board's expectations. Costs continue to be tightly controlled to maximise the cash runway and operating costs are currently c.£750k/month.

 

Outlook

 

The Group continues to make solid progress in commercialisation of CFQDs and expects to announce further orders from its healthy pipeline of projects. With the market continuing to develop more slowly than originally anticipated, we remain focused on careful management of costs ahead of the anticipated sales ramp-up. The Board remains confident that the opportunity for CFQDs, both in Display and in other sectors, remains exciting and, moreover, that the Company has a competitive lead in this technology.

 

Nanoco expects to announce its preliminary results for the year ended 31 July 2017 in October 2017.

 

This announcement contains inside information.

 

For further information, please contact:

 

Nanoco Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

David Blain, Chief Financial Officer

Caroline Watson, Investor Relations Manager Tel: + 44 (0) 7799 897357

cwatson@nanocotechnologies.com 

Peel Hunt Tel: +44 (0) 20 7418 8900

Adrian Trimmings

George Sellar

MHP Communications Tel: +44 (0) 20 3128 8570

Reg Hoare / Andrew Leach / Giles Robinson / Peter Lambie

nanoco@mhpc.com 

Notes for editors:

 

About Nanoco Group plc

 

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, Nanoco has non-exclusive manufacturing and marketing licensing agreements with The Dow Chemical Company, Merck KGaA and Taiwan's Wah Hong Industrial Corporation. Nanoco also has a strategy of direct sales in display and in its other target markets, including lighting.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTOKQDBCBKDPFB
Date   Source Headline
25th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
24th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
23rd Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Apr 20244:06 pmRNSTR-1: Notification of Major Holdings
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20243:02 pmRNSExercise of Deferred Bonus Options
18th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
17th Apr 20241:56 pmRNSNotification of Major Holdings
17th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
16th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Apr 20244:10 pmRNSDirector/PDMR Shareholding
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Apr 20247:00 amRNSResult of Tender Offer
28th Mar 202412:52 pmRNSGeneral Meeting - Voting Results
27th Mar 20247:00 amRNSInterim Results
11th Mar 202412:47 pmRNSPosting of Circular
11th Mar 20247:00 amRNSProposed return of up to £33.0 million
8th Feb 20247:00 amRNSHalf Year Trading Update
7th Feb 202411:23 amRNSDirector Declaration
24th Jan 20247:00 amRNSReceipt of Final Litigation Proceeds
23rd Jan 20244:02 pmRNSNotification Of Transactions By PDMR
16th Jan 20243:40 pmRNSDirector/PDMR Shareholding
15th Jan 20244:35 pmRNSHolding(s) in Company
12th Jan 20249:45 amRNSJoint Development Agreement with European Customer
22nd Dec 20237:00 amRNSAppointment of Financial Adviser and Joint Broker
21st Dec 202312:00 pmRNSAppointments of Non-Executive Directors
12th Dec 20239:35 amRNSBlocklisting six-monthly return
7th Dec 20233:23 pmRNSResult of AGM
7th Dec 20237:00 amRNSAGM Statement & Trading Update
15th Nov 20237:00 amRNSFirst ever commercial production order
13th Nov 20234:28 pmRNS2023 Annual Report and Notice of AGM
7th Nov 20237:00 amRNSJoint Development Agreement with Asian Customer
2nd Nov 20232:18 pmRNSHolding(s) in Company
17th Oct 20237:00 amRNSUnaudited Preliminary Results
10th Oct 20237:00 amRNSNotice of Results
3rd Oct 20234:32 pmRNSForeign Currency Hedge of Litigation Settlement
14th Aug 20233:58 pmRNSResult of Meeting
8th Aug 20237:00 amRNSTrading Update
7th Aug 20237:00 amRNSGlass Lewis recommends to support Nanoco’s Board
2nd Aug 20237:00 amRNSHolding(s) in Company
2nd Aug 20237:00 amRNSISS recommendation to support Nanoco’s Board
1st Aug 20237:13 amRNSTotal Voting Rights
28th Jul 20235:23 pmRNSDirector/PDMR Shareholding
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.